Soon after, in 2017, the combination of dabrafenib plus trametinib was approved based on the results of the COMBI-AD trial as adjuvant therapy for patients with BRAF V600 mutation–positive stage III melanoma.51 The 3-year RFS was 58% with the combination therapy and 39% with placebo. Here, BRAF is linked to melanoma.